Guenther Koehne, MD, PhD

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.

Guenther Koehne, MD, PhD, discusses findings from a phase 1/2 trial that are being presented at the American Society of Hematology 2023 Annual Meeting.

Allogeneic transplant is, today, a curative therapy for a variety of blood cancers, including many cases of acute monocytic leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.

Gunther Koehne, MD, PhD, discusses his hopes for future advances for patients with hematologic malignancies.

The excitement surrounding advances and improved outcomes in very difficult-to-treat diseases is palpable. Yet the complexities of these therapies also bring their own complications.

As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

While the volume and variety of information coming from current studies seems overwhelming, it is what is changing the cancer care environment today.